Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Target price


WKN: A2ALQV / Name: Reata Pharms / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Reata Pharmaceuticals Inc Stock

So far the community has only identified positive things for Reata Pharmaceuticals Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".

Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that focuses on identifying, developing, and commercializing novel therapeutics for patients with severe and life-threatening diseases. The company's primary business areas include drug discovery and development in fields such as cardiovascular, fibrotic, mitochondrial, and neurodegenerative diseases. With a strong emphasis on research and innovation, Reata Pharmaceuticals seeks to deliver cutting-edge treatments that address unmet medical needs, improve patient outcomes, and significantly impact the lives of those suffering from rare and debilitating conditions. As a publicly traded company, Reata Pharmaceuticals is listed on the NASDAQ stock exchange under the ticker symbol "RETA."

Pros and Cons of Reata Pharmaceuticals Inc in the next few years

G***** c******* t* c**********
C******** o* t** e**********
S********** s********
W********* I********* f** t** n*** y****
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Reata Pharmaceuticals Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Reata Pharmaceuticals Inc - - - - - - -
Immunic Inc. -2.970% 2.320% 6.625% -30.635% -16.713% -88.962% -
NanoViricides Inc. -0.530% 3.911% 82.353% 78.846% 96.825% -35.685% -56.804%
Ocuphire Pharma Inc. -1.880% -0.257% -5.488% -61.491% -44.544% - -

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17

Reata Pharms, a company operating within the Biotechnology & Medical Research industry, presents a mix of both encouraging and concerning financial figures. Their financial statements reveal a rapid growth in assets and research & development (R&D) expenditures, which is indicative of a company investing in its future. However, Reata Pharms' increasing net losses and negative stockholder equity may raise concerns among investors. The following detailed analysis explores the pros and cons of the company's financial position.

*Pros: *

Growing total assets: Reata Pharms has seen growth in its total assets over the years, increasing from 857,598,000 USD in 2020 to 735,016,000 USD in 2021, and finally reaching 514,491,000 USD as of 2022-12-31. This growth reflects a company that continues to create value for its stakeholders.


The comment is under review

The comment is under review

Recently, many factors have affected Reata Pharmaceuticals, so the stock can rise or fall differently. However, I kept it until the end. It shows me the case of  <a">monkey mart</a> . After I sold it all, its stock went up again. Therefore, I will not do so in this case.
Show more